rethinkTHC Search
Menu
Study breakdown

Full-Spectrum Cannabis Extract Outperformed CBD Alone in Reducing Brain Cell Inflammation

Animal StudyPreliminary evidence
The takeaway

A full-spectrum low-THC cannabis extract (NTI-164) significantly reduced microglial inflammation markers and protected neurons from excitotoxic damage in cell models, while CBD alone did not achieve the same anti-inflammatory effects.

Cannabis pharmacology researchers, neuroinflammation researchers, medical cannabis formulators

Full-spectrum extract reduced inflammation; CBD alone did not

What the researchers found

NTI-164, a high-CBD/low-THC full-spectrum extract, significantly attenuated inflammation-induced upregulation of microglial inflammatory markers in BV-2 microglia, while CBD alone did not. NTI-164 also promoted neuron proliferation and survival under excitotoxic conditions in SHSY-5Y neurons.

Why it matters

This study provides direct evidence for the "entourage effect," showing that a whole-plant extract can outperform an isolated cannabinoid. The neuroprotective findings are relevant to conditions like autism spectrum disorder where neuroinflammation plays a role.

The numbers in context

NTI-164 significantly attenuated microglial inflammatory markers; CBD alone did not; NTI-164 promoted neuron proliferation and survival under excitotoxic conditions.

How the study worked

In vitro study using BV-2 microglial cells and SHSY-5Y neurons to compare anti-inflammatory and neuroprotective effects of a full-spectrum cannabis extract (NTI-164) versus CBD alone.

What this study cannot tell us

In vitro study using cell lines, not living brain tissue. Cannot extrapolate directly to human disease. NTI-164 is a specific proprietary extract that may not represent all full-spectrum products.

How to read the evidence

In vitro cell study with controlled comparisons, but no in vivo or human data.

When this study was published

2024 publication

The bigger picture

The debate between isolated CBD and full-spectrum extracts has major implications for medical cannabis formulation. These in vitro results suggest that minor cannabinoids and terpenes in whole-plant extracts may contribute meaningfully to therapeutic effects.

Questions still open

  • Which specific minor cannabinoids or terpenes in NTI-164 contribute to its superior anti-inflammatory effects?
  • Would these in vitro advantages translate to clinical benefits in neuroinflammatory conditions?

Common questions

Is full-spectrum cannabis better than CBD alone?
In this cell study, a full-spectrum low-THC extract significantly reduced brain cell inflammation while CBD alone did not. This supports the "entourage effect" concept, though human studies are needed to confirm.
Can cannabis extracts protect brain cells?
This in vitro study found a full-spectrum cannabis extract promoted neuron survival under conditions that mimic brain damage. These are preliminary findings in cell models, not in living brains.

Read the original research

Evaluation of the Efficacy of a Full-Spectrum Low-THC Cannabis Plant Extract Using In Vitro Models of Inflammation and Excitotoxicity.

Biomolecules, 14(11)

Citation

Ross-Munro, Emily; Isikgel, Esra; Fleiss, Bobbi. (2024). Evaluation of the Efficacy of a Full-Spectrum Low-THC Cannabis Plant Extract Using In Vitro Models of Inflammation and Excitotoxicity.. Biomolecules, 14(11). https://doi.org/10.3390/biom14111434

Explore the wider topic